{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:46:13Z","timestamp":1767797173621,"version":"3.49.0"},"reference-count":42,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Young Talent of Lifting engineering for Science and Technology in Shandong, China","award":["SDAST2025QTB062"],"award-info":[{"award-number":["SDAST2025QTB062"]}]},{"name":"Beijing University of Chinese Medicine, Centre of Evidence-Based Chinese Medicine","award":["20210017"],"award-info":[{"award-number":["20210017"]}]},{"name":"National Natural Science Foundation Project in China","award":["82274471"],"award-info":[{"award-number":["82274471"]}]},{"name":"Youth project of the Natural Science Foundation of Shandong Province","award":["ZR2021QH219"],"award-info":[{"award-number":["ZR2021QH219"]}]},{"name":"Science Project for Medicine and Health of Shandong Province","award":["202303010788"],"award-info":[{"award-number":["202303010788"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tongxinluo capsule (TXL) is widely used in China as an adjunctive therapy for patients with acute coronary syndromes (ACS) who underwent percutaneous coronary intervention (PCI), collectively referred to as ACS-PCI. However, current evidence on its therapeutic effects and safety remains limited and insufficiently synthesised. This review aims to evaluate the therapeutic effects and safety of adding TXL to Western medical therapy (WM) in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was performed in PubMed, the Cochrane Library, CNKI, VIP and Wanfang from inception to August 2024; a rapid supplemental search was conducted up to November 2025, without language restrictions, to identify randomised controlled trials (RCTs) evaluating the therapeutic effects and safety of adding TXL to WM in patients with ACS-PCI. Dichotomous outcomes were summarised using risk ratios (RRs) with 95% CIs; absolute risk reductions (ARRs) were estimated as risk differences, and corresponding numbers needed to treat (NNTs) were calculated. Continuous outcomes were summarised using mean differences (MDs) with 95% CIs. All meta-analyses were performed using a random-effects model. The included studies generally had limitations in methodological quality, heterogeneity across analyses was low to moderate and the potential for publication bias could not be excluded. The evidence certainty for each outcome was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen RCTs involving 1800 participants were included. Low-certainty evidence indicated that adding TXL to WM may reduce the risks of restenosis (RR=0.30, 95%\u2009CI 0.10 to 0.91; ARR=0.056, NNT=18), revascularisation (RR=0.28, 95%\u2009CI 0.10 to 0.80; ARR=0.069, NNT=15), myocardial infarction (RR=0.44, 95%\u2009CI 0.20 to 0.98; ARR=0.033, NNT=31), angina (RR=0.32, 95%\u2009CI 0.17 to 0.61; ARR=0.076, NNT=14) and other cardiovascular events (RR=0.41, 95%\u2009CI 0.24 to 0.71; ARR=0.075, NNT=14). It also improved Seattle Angina Questionnaire scores (MD=8.82, 95%\u2009CI 6.58 to 11.05) and quality of life (qualitative synthesis). However, no statistically significant reductions were observed for sudden cardiac death (RR=0.39, 95%\u2009CI 0.12 to 1.27; ARR=0.022, NNT=45), or non-cardiovascular adverse events (RR=0.67, 95%\u2009CI 0.32 to 1.40; ARR=0.043, NNT=24) when TXL was added to WM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current evidence suggests that adjunctive TXL may reduce key cardiovascular events and improve symptoms and quality of life in patients with ACS-PCI, without increasing the risk of non-cardiovascular adverse events. However, all findings are based on low-certainty evidence. These results provide preliminary support for the use of TXL as an adjunctive therapy, but high-quality, multicentre RCTs are needed to confirm these effects and inform clinical guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024509453.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-111565","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T16:10:31Z","timestamp":1767111031000},"page":"e111565","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive Tongxinluo capsule for patients with acute coronary syndromes undergoing percutaneous coronary intervention: a GRADE-assessed systematic review and meta-analysis of randomised controlled trials"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5107","authenticated-orcid":false,"given":"Shi-Bing","family":"Liang","sequence":"first","affiliation":[{"name":"Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"},{"name":"Centre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Postdoctoral Research Station, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"},{"name":"Centre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5997-3525","authenticated-orcid":false,"given":"Yu-Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jing","family":"Chen","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shuo","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Emergency Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Hua","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Zheng","sequence":"additional","affiliation":[{"name":"Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China"},{"name":"Centre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-Chao","family":"Niu","sequence":"additional","affiliation":[{"name":"Postdoctoral Research Station, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China"},{"name":"Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Tai\u2019an, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Robinson","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, Beijing, China"},{"name":"Institute of Health and Social Care, London South Bank University, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Lun","family":"Li","sequence":"additional","affiliation":[{"name":"Cardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Tai\u2019an, China"},{"name":"The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China"},{"name":"Shandong Engineering Laboratory of Traditional Chinese Medicine Precision Therapy for Cardiovascular Diseases"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"key":"2026010703492180000_15.12.e111565.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"2026010703492180000_15.12.e111565.2","doi-asserted-by":"publisher","DOI":"10.1093\/ehjacc\/zuad107"},{"key":"2026010703492180000_15.12.e111565.3","first-page":"34","article-title":"Acute Coronary Syndrome: Diagnosis and Initial Management","volume":"109","author":"Nohria","year":"2024","journal-title":"Am Fam Physician"},{"key":"2026010703492180000_15.12.e111565.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(02)02489-X"},{"key":"2026010703492180000_15.12.e111565.5","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)02391-6","article-title":"Acute coronary syndromes","volume":"399","author":"Bergmark","year":"2022","journal-title":"Lancet"},{"key":"2026010703492180000_15.12.e111565.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0358"},{"key":"2026010703492180000_15.12.e111565.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2011.05.005"},{"key":"2026010703492180000_15.12.e111565.8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijcard.2007.10.032","article-title":"An angiographic evaluation of restenosis rate at a six-month follow-up of patients with ST-elevation myocardial infarction submitted to primary percutaneous coronary intervention","volume":"131","author":"Giglioli","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026010703492180000_15.12.e111565.9","doi-asserted-by":"crossref","first-page":"805266","DOI":"10.3389\/fphar.2022.805266","article-title":"Tongxinluo May Alleviate Inflammation and Improve the Stability of Atherosclerotic Plaques by Changing the Intestinal Flora","volume":"13","author":"Qi","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026010703492180000_15.12.e111565.10","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.2023.19712","article-title":"Traditional Chinese Medicine for ST-Segment Elevation Myocardial Infarction","volume":"330","author":"Curfman","year":"2023","journal-title":"JAMA"},{"key":"2026010703492180000_15.12.e111565.11","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fphar.2018.00830","article-title":"Potential Effectiveness of Chinese Patent Medicine Tongxinluo Capsule for Secondary Prevention After Acute Myocardial Infarction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"2026010703492180000_15.12.e111565.12","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1001\/jama.2023.19524","article-title":"Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction","volume":"330","author":"Yang","year":"2023","journal-title":"JAMA"},{"key":"2026010703492180000_15.12.e111565.13","first-page":"CD010237","article-title":"Tong-xin-luo capsule for patients with coronary heart disease after percutaneous coronary intervention","volume":"2015","author":"Mao","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703492180000_15.12.e111565.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2026010703492180000_15.12.e111565.15","unstructured":"The Cochrane Collaboration . Review manager (RevMan) [computer program]. version5.4. 2020."},{"key":"2026010703492180000_15.12.e111565.16","unstructured":"The NNT group . The NNT, explained. 2022. Available: https:\/\/www.thennt.com"},{"key":"2026010703492180000_15.12.e111565.17","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions version 6.4 . Cochrane, 2023. Available: www.training.cochrane.org\/handbook"},{"key":"2026010703492180000_15.12.e111565.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2026010703492180000_15.12.e111565.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39490.551019.BE"},{"key":"2026010703492180000_15.12.e111565.20","first-page":"965","article-title":"Observation of the efficacy of Tongxinluo Capsules in patients with acute myocardial infarction after PCI","volume":"41","author":"Sang","year":"2025","journal-title":"J Pract Tradit Chin Med"},{"key":"2026010703492180000_15.12.e111565.21","first-page":"8","article-title":"The value of Tongxinluo Capsule in patients after PCI for acute myocardial infarction","volume":"24","author":"Zhang","year":"2024","journal-title":"Pract Clin J Integr Tradit Chin West Med"},{"key":"2026010703492180000_15.12.e111565.22","first-page":"44","article-title":"Clinical effect of Tongxinluo Capsule combined with clopidogrel bisulfate tablets in the treatment of patients after PCI for acute myocardial infarction","volume":"17","author":"Xu","year":"2024","journal-title":"Clin J Clin Ration Drug Use"},{"key":"2026010703492180000_15.12.e111565.23","first-page":"122","article-title":"Observation on the effect of Tongxinluo Capsule combined with nicorandil on vascular endothelial cell function and myocardial enzyme profile in patients after PCI for acute myocardial infarction","volume":"43","year":"2023","journal-title":"Harbin Med J"},{"key":"2026010703492180000_15.12.e111565.24","first-page":"57","article-title":"Effect of Tongxinluo Capsule on plasma endothelin-1, vascular endothelial growth factor and micro RNA-155 levels after percutaneous coronary intervention in patients with acute coronary syndrome","volume":"23","author":"Liang","year":"2023","journal-title":"Cardio-Cerebrovasc Dis Prev Treat"},{"key":"2026010703492180000_15.12.e111565.25","first-page":"1649","article-title":"Effects of Tongxinluo Capsule combined with clopidogrel bisulfate after PCI in patients with acute myocardial infarction","volume":"16","author":"Wang","year":"2021","journal-title":"World Chin Med"},{"key":"2026010703492180000_15.12.e111565.26","first-page":"37","article-title":"Clinical effect of Tongxinluo Capsule adjuvant to aspirin and isosorbide mononitrate in the treatment of acute myocardial infarction in patients with PCI after surgery","volume":"14","author":"Hong","year":"2021","journal-title":"Clin J Clin Ration Drug Use"},{"key":"2026010703492180000_15.12.e111565.27","first-page":"3084","article-title":"Clinical study of Tongxinluo Combined with ticagrelor in the treatment of acute coronary syndrome undergoing PCI","volume":"15","author":"Chen","year":"2020","journal-title":"World Chin Med"},{"key":"2026010703492180000_15.12.e111565.28","first-page":"1095","article-title":"Effects of Tongxinluo Capsule combined with atorvastatin on serum vWF, hs-CRP and VEGF levels in patients with acute coronary syndrome after PCI","volume":"32","author":"Wang","year":"2019","journal-title":"Chin J Clin Res"},{"key":"2026010703492180000_15.12.e111565.29","first-page":"111","article-title":"Clinical study on Tongxinluo Capsules combined with Tirofiban for acute myocardial infarction in PCI perioperative period","volume":"51","author":"Xu","year":"2019","journal-title":"J New Chin Med"},{"key":"2026010703492180000_15.12.e111565.30","first-page":"36","article-title":"Clinical study on Tongxinluo Capsules combined with atorvastatin in treatment of acute myocardial infarction with PCI postoperative inflammatory reaction","volume":"30","author":"Li","year":"2015","journal-title":"Drugs & Clin"},{"key":"2026010703492180000_15.12.e111565.31","first-page":"20","article-title":"Tongxinluo intervention of patients with acute coronary syndrome after PIC surgery","volume":"7","author":"Geng","year":"2015","journal-title":"Clin J Chin Med"},{"key":"2026010703492180000_15.12.e111565.32","first-page":"196","article-title":"Tongxinluo Capsule on acute myocardial infarction after percutaneous coronary artery interventional therapy after operation in 30 cases","volume":"20","author":"Tian","year":"2014","journal-title":"Chin J Exp Tradit Med Formulae"},{"key":"2026010703492180000_15.12.e111565.33","first-page":"1865","article-title":"Effect of Tongxinluo Capsule on inflammatory factors and vascular endothelial function after percutaneous coronary intervention in patients with acute myocardial infarction","volume":"6","author":"Dong","year":"2012","journal-title":"Chin J Clin"},{"key":"2026010703492180000_15.12.e111565.34","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3736\/jcim20110504","article-title":"Effect of Tongxinluo Capsule on platelet activities and vascular endothelial functions as well as prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"31","author":"Chen","year":"2011","journal-title":"Chin J Integr Tradit West Med"},{"key":"2026010703492180000_15.12.e111565.35","first-page":"175","article-title":"The effect of Tongxinluo Capsules on coronary restennosis of patients with acute myocardial infarction after percutaneoas coronary intervention","volume":"17","author":"Liang","year":"2010","journal-title":"Chin J TCM WM Crit Care"},{"key":"2026010703492180000_15.12.e111565.36","first-page":"487","article-title":"The effect of Tongxinluo Capsule on level of serum CRP and blood lipid in patients with ACS post PCI","volume":"9","author":"Zheng","year":"2010","journal-title":"Chin J Diffic Compl Cas"},{"key":"2026010703492180000_15.12.e111565.37","first-page":"2858","article-title":"No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial)","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J (Engl)"},{"key":"2026010703492180000_15.12.e111565.38","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eujim.2013.07.011","article-title":"GP-TCM unabridged guidelines for randomised controlled trials investigating Chinese herbal medicine (CHM)","volume":"6","author":"Flower","year":"2014","journal-title":"Eur J Integr Med"},{"key":"2026010703492180000_15.12.e111565.39","article-title":"Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions","volume":"2","author":"Nguyen","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"key":"2026010703492180000_15.12.e111565.40","first-page":"337","article-title":"Systemic review on safety of Tongxinluo Capsules","volume":"5","author":"Zhang","year":"2013","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"2026010703492180000_15.12.e111565.41","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7586","article-title":"SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials","volume":"346","author":"Chan","year":"2013","journal-title":"BMJ"},{"key":"2026010703492180000_15.12.e111565.42","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-111565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:53:35Z","timestamp":1767786815000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-111565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,30]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2025-111565"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-111565","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}